Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Sales (2018 - 2025)

BioNexus Gene Lab's Return on Sales history spans 8 years, with the latest figure at 0.28% for Q3 2025.

  • For Q3 2025, Return on Sales rose 29.0% year-over-year to 0.28%; the TTM value through Sep 2025 reached 0.24%, down 13.0%, while the annual FY2024 figure was 0.17%, 10.0% up from the prior year.
  • Return on Sales for Q3 2025 was 0.28% at BioNexus Gene Lab, down from 0.27% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.8% in Q1 2021 and bottomed at 1.02% in Q3 2023.
  • The 5-year median for Return on Sales is 0.03% (2024), against an average of 0.09%.
  • The largest YoY upside for Return on Sales was 45bps in 2021 against a maximum downside of -995bps in 2021.
  • A 5-year view of Return on Sales shows it stood at 0.04% in 2021, then tumbled by -152bps to 0.02% in 2022, then skyrocketed by 939bps to 0.15% in 2023, then tumbled by -187bps to 0.14% in 2024, then tumbled by -106bps to 0.28% in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Return on Sales are 0.28% (Q3 2025), 0.27% (Q2 2025), and 0.29% (Q1 2025).